Vaxart, Inc.

119 articles with Vaxart, Inc.

• Vaxart Hosting Key Opinion Leader Meeting on the Health Economics of Norovirus DiseaseNorovirus represents a $3+billion U.S. market opportunity

  11/6/2019

  Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that it will host a key opinion leader (KOL) meeting on the health economics of norovirus disease on Thursday, November 14th in New York City.

• Vaxart, Inc. Announces Changes to its Board of DirectorsThe company has appointed four new members to the Board of Directors

  10/28/2019

  Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that four new members have been appointed to the Board of Directors effective immediately.

• Vaxart to Present at the H.C. Wainwright 21st Annual Global Investment Conference

  9/4/2019

  Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Wouter Latour, M.D., president and chief executive officer of Vaxart, will present a company update and overview at the H.C. Wainwright 21st Annual Global Investment Conference on Tuesday, September 10, 2019, at 12:30 p.m. EST in New York.

• Vaxart Announces Second Quarter 2019 Financial Results and Provides Corporate Update

  8/8/2019

  Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced financial results for the second quarter ended June 30, 2019.

• Vaxart Enters into Research Collaboration with Janssen to Evaluate Oral Universal Influenza Vaccine

  7/9/2019

  Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model

• Vaxart to Present at ASM Microbe 2019

  6/20/2019

  Vaxart, Inc. announced that Roberto Mateo, Ph.D., senior scientist at Vaxart, will present preclinical results of its oral Respiratory Syncytial Virus vaccine in a poster presentation at the American Society of Microbiology 2019, taking place from June 20-24, 2019 in San Francisco, California.

• New Publication in Vaccine Highlights Preclinical Results of Vaxart’s Mucosal Chikungunya Vaccine

  5/29/2019

  Vaxart, Inc. announced the publication of the comprehensive results from a preclinical trial of its chikungunya vaccine in the peer reviewed journal, Vaccine.

• Vaxart Doses First Patient in Randomized Cohort of Bivalent Norovirus Vaccine Phase 1b Clinical Trial

  4/16/2019

  Vaxart, Inc. announced it has started dosing subjects in the randomized cohort of the Phase 1b bivalent norovirus vaccine clinical trial.

• Vaxart to Present at the 29th European Congress of Clinical Microbiology & Infectious Diseases

  4/12/2019

  100% Survival Against Lethal H5N1 Avian Flu Challenge in Ferret Study

• Vaxart Announces Pricing of Underwritten Public Offering

  4/9/2019

  Vaxart, Inc. announced the pricing of an underwritten public offering of 9,090,010 shares of common stock, and common warrants to purchase up to an aggregate of 9,090,010 shares of common stock.

• Vaxart to Present at Global Medical Meetings in April

  3/28/2019

  Vaxart, Inc. announced participation in two upcoming global medical meetings in April.

• Vaxart Completes Dosing of the Lead-In Cohort in Bivalent Norovirus Vaccine Phase 1b Clinical Trial

  3/27/2019

  Vaxart, Inc. announced the completion of dosing of the lead-in cohort in the Phase 1b bivalent norovirus vaccine clinical trial with its oral norovirus GII.4 vaccine.

• 

  Biotechs by the Bay Boom With Business Bounty

  3/25/2019

  When it comes to biotech and pharma innovation few places stand out like the Biotech Bay. The area is home to a plethora of innovative companies that are shaping the future of medical treatment for a variety of diseases and conditions on a daily basis.

• Vaxart Announces Closing of Registered Direct Offering of Common Stock

  3/20/2019

  Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the closing of its previously announced registered direct offering of 1,200,000 shares of its common stock at a price of $2.50 per share

• Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial

  3/19/2019

  First Dosing with Norovirus GII.4 Oral Tablet Vaccine Scheduled for Week of March 18

• Vaxart Announces $3 Million Registered Direct Offering Priced At-the-Market

  3/19/2019

  Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale in a registered direct offering priced at-the-market of 1,200,000 shares of the Vaxart’s common stock,

• Vaxart Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update

  2/6/2019

  Initiation of Two Norovirus Vaccine Trials Expected in 1H 2019

• Vaxart to Present at World Vaccine and Immunotherapy Congress West Coast 2018

  11/28/2018

  Vaxart, Inc. today announced that Sean Tucker, Ph.D., chief scientific officer, will present summary data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at the World Vaccine and Immunotherapy Congress West Coast 2018, taking place from November 28-30, 2018 in San Diego, California.

• 

  BioSpace Movers and Shakers for Oct. 15

  10/15/2018

  Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.

• New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart’s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity

  10/4/2018

  Vaxart oral tablet vaccine provided 39% reduction in flu illness compared to 27% for Fluzone®